Professional
Added to YB: 2025-04-11
Pitch date: 2025-04-08
VRTX [bullish]
Vertex Pharmaceuticals Incorporated
+2.01%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.
Market Cap
$119.5B
Pitch Price
$460.02
Price Target
N/A
Dividend
N/A
EV/EBITDA
21.37
P/E
30.70
EV/Sales
9.10
Sector
Biotechnology
Category
growth
Show full summary:
GreensKeeper Value Fund Portfolio Holding: Vertex Pharmaceuticals Incorporated
VRTX (holding update): +20.4% Q4. CF franchise driving FCF. Launched Alyftrek (CF, once-daily, 31 new mutations) & Journavx (non-opioid pain). Journavx potential blockbuster. Developing chronic pain therapies. Success could combat opioid crisis & boost shareholder value. Diversifying portfolio beyond CF.
Read full article (1 min)